Anusha Kalbasi

Assistant Professor-in-Residence, Radiation Oncology, University of California Los Angeles

Publications

  1. Kalbasi A, Siurala M, Su LL, Tariveranmoshabad M, Picton LK, Ravikumar P, Li P, Lin JX, Escuin-Ordinas H, Da T, Kremer SV, Sun AL, Castelli S, Agarwal S, Scholler J, Song D, Rommel PC, Radaelli E, Young RM, Leonard WJ, Ribas A, June CH, Garcia KC. Potentiating adoptive cell therapy using synthetic IL-9 receptors.. Nature, 2022.
  2. Chantharasamee J, Wong K, Potivongsajarn P, Qorbani A, Motamed N, Brackert S, Cohen J, Chmielowski B, Kalbasi A, Rao J, Nelson S, Singh A. Retrospective analysis of adjuvant treatment for localized, operable uterine leiomyosarcoma.. Cancer medicine, 2022.
  3. Campbell KM, Thaker M, Medina E, Kalbasi A, Singh A, Ribas A, Nowicki TS. Spatial profiling reveals association between WNT pathway activation and T-cell exclusion in acquired resistance of synovial sarcoma to NY-ESO-1 transgenic T-cell therapy.. Journal for immunotherapy of cancer, 2022.
  4. Weidhaas J, Marco N, Scheffler AW, Kalbasi A, Wilenius K, Rietdorf E, Gill J, Heilig M, Desler C, Chin RK, Kaprealian T, McCloskey S, Raldow A, Raja NP, Kesari S, Carrillo J, Drakaki A, Scholz M, Telesca D. Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy.. Journal for immunotherapy of cancer, 2022.
  5. Valle LF, Bernthal N, Eilber FC, Shabason JE, Bedi M, Kalbasi A. Evaluating Thresholds to Adopt Hypofractionated Preoperative Radiotherapy as Standard of Care in Sarcoma.. Sarcoma, 2021.
  6. Gao Y, Ghodrati V, Kalbasi A, Fu J, Ruan D, Cao M, Wang C, Eilber FC, Bernthal N, Bukata S, Dry SM, Nelson SD, Kamrava M, Lewis J, Low DA, Steinberg M, Hu P, Yang Y. Prediction of soft tissue sarcoma response to radiotherapy using longitudinal diffusion MRI and a deep neural network with generative adversarial network-based data augmentation.. Medical physics, 2021.
  7. Reddy VK, Jain V, Venigalla S, Levin WP, Wilson RJ, Weber KL, Kalbasi A, Sebro RA, Shabason JE. Radiotherapy Remains Underused in the Treatment of Soft-Tissue Sarcomas: Disparities in Practice Patterns in the United States.. Journal of the National Comprehensive Cancer Network : JNCCN, 2021.
  8. Li J, Duran MA, Dhanota N, Chatila WK, Bettigole SE, Kwon J, Sriram RK, Humphries MP, Salto-Tellez M, James JA, Hanna MG, Melms JC, Vallabhaneni S, Litchfield K, Usaite I, Biswas D, Bareja R, Li HW, Martin ML, Dorsaint P, Cavallo JA, Li P, Pauli C, Gottesdiener L, DiPardo BJ, Hollmann TJ, Merghoub T, Wen HY, Reis-Filho JS, Riaz N, Su SM, Kalbasi A, Vasan N, Powell SN, Wolchok JD, Elemento O, Swanton C, Shoushtari AN, Parkes EE, Izar B, Bakhoum SF. Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis.. Cancer discovery, 2020.
  9. Gao Y, Yoon S, Savjani R, Pham J, Kalbasi A, Raldow A, Low DA, Hu P, Yang Y. Comparison and evaluation of distortion correction techniques on an MR-guided radiotherapy system.. Medical physics, 2020.
  10. Grasso CS, Tsoi J, Onyshchenko M, Abril-Rodriguez G, Ross-Macdonald P, Wind-Rotolo M, Champhekar A, Medina E, Torrejon DY, Shin DS, Tran P, Kim YJ, Puig-Saus C, Campbell K, Vega-Crespo A, Quist M, Martignier C, Luke JJ, Wolchok JD, Johnson DB, Chmielowski B, Hodi FS, Bhatia S, Sharfman W, Urba WJ, Slingluff CL, Diab A, Haanen JBAG, Algarra SM, Pardoll DM, Anagnostou V, Topalian SL, Velculescu VE, Speiser DE, Kalbasi A, Ribas A. Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.. Cancer cell, 2020.
  11. Kalbasi A, Tariveranmoshabad M, Hakimi K, Kremer S, Campbell KM, Funes JM, Vega-Crespo A, Parisi G, Champekar A, Nguyen C, Torrejon D, Shin D, Zaretsky JM, Damoiseaux RD, Speiser DE, Lopez-Casas PP, Quintero M, Ribas A. Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma.. Science translational medicine, 2020.
  12. Grasso CS, Tsoi J, Onyshchenko M, Abril-Rodriguez G, Ross-Macdonald P, Wind-Rotolo M, Champhekar A, Medina E, Torrejon DY, Shin DS, Tran P, Kim YJ, Puig-Saus C, Campbell K, Vega-Crespo A, Quist M, Martignier C, Luke JJ, Wolchok JD, Johnson DB, Chmielowski B, Hodi FS, Bhatia S, Sharfman W, Urba WJ, Slingluff CL, Diab A, Haanen JBAG, Algarra SM, Pardoll DM, Anagnostou V, Topalian SL, Velculescu VE, Speiser DE, Kalbasi A, Ribas A. Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.. Cancer cell, 2020.
  13. Gao Y, Kalbasi A, Hsu W, Ruan D, Fu J, Shao J, Cao M, Wang C, Eilber FC, Bernthal N, Bukata S, Dry SM, Nelson SD, Kamrava M, Lewis J, Low DA, Steinberg M, Hu P, Yang Y. Treatment effect prediction for sarcoma patients treated with preoperative radiotherapy using radiomics features from longitudinal diffusion-weighted MRIs.. Physics in medicine and biology, 2020.
  14. Graham DS, van Dams R, Jackson NJ, Onyshchenko M, Eckardt MA, DiPardo BJ, Nelson SD, Chmielowski B, Shabason JE, Singh AS, Eilber FC, Kalbasi A. Chemotherapy and Survival in Patients with Primary High-Grade Extremity and Trunk Soft Tissue Sarcoma.. Cancers, 2020.
  15. Graham DS, Onyshchenko M, Eckardt MA, DiPardo BJ, Venigalla S, Nelson SD, Chmielowski B, Singh AS, Shabason JE, Eilber FC, Kalbasi A. Low Rates of Chemotherapy Use for Primary, High-Grade Soft Tissue Sarcoma: A National Cancer Database Analysis.. Journal of the National Comprehensive Cancer Network : JNCCN, 2020.
  16. Campbell KM, Steiner G, Wells DK, Ribas A, Kalbasi A. Prioritization of SARS-CoV-2 epitopes using a pan-HLA and global population inference approach.. bioRxiv : the preprint server for biology, 2020.
  17. Qi XS, Chu FI, Zhang Z, Chin RK, Raldow A, Kishan AU, Lee P, Chang A, Kalbasi A, Kamrava M, Steinberg ML, Low DA. Clinical Development and Evaluation of Megavoltage Topogram for Fast Patient Alignment on Helical Tomotherapy.. Advances in radiation oncology, 2020.
  18. Torrejon DY, Abril-Rodriguez G, Champhekar AS, Tsoi J, Campbell KM, Kalbasi A, Parisi G, Zaretsky JM, Garcia-Diaz A, Puig-Saus C, Cheung-Lau G, Wohlwender T, Krystofinski P, Vega-Crespo A, Lee CM, Mascaro P, Grasso CS, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Ribas A. Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade.. Cancer discovery, 2020.
  19. Schaefer IM, Hong K, Kalbasi A. How Technology Is Improving the Multidisciplinary Care of Sarcoma.. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2020.
  20. Nesseler JP, Lee MH, Nguyen C, Kalbasi A, Sayre JW, Romero T, Nickers P, McBride WH, Schaue D. Tumor Size Matters-Understanding Concomitant Tumor Immunity in the Context of Hypofractionated Radiotherapy with Immunotherapy.. Cancers, 2020.
  21. Kalbasi A, Kamrava M, Chu FI, Telesca D, Van Dams R, Yang Y, Ruan D, Nelson SD, Dry SM, Hernandez J, Chmielowski B, Singh AS, Bukata SV, Bernthal NM, Steinberg ML, Weidhaas JB, Eilber FC. A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2020.
  22. Abril-Rodriguez G, Torrejon DY, Liu W, Zaretsky JM, Nowicki TS, Tsoi J, Puig-Saus C, Baselga-Carretero I, Medina E, Quist MJ, Garcia AJ, Senapedis W, Baloglu E, Kalbasi A, Cheung-Lau G, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Wang CY, Grasso CS, Ribas A. Publisher Correction: PAK4 inhibition improves PD-1 blockade immunotherapy.. Nature cancer, 2020.
  23. Abril-Rodriguez G, Torrejon DY, Liu W, Zaretsky JM, Nowicki TS, Tsoi J, Puig-Saus C, Baselga-Carretero I, Medina E, Quist MJ, Garcia AJ, Senapedis W, Baloglu E, Kalbasi A, Cheung-Lau G, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Wang CY, Grasso CS, Ribas A. PAK4 inhibition improves PD-1 blockade immunotherapy.. Nature cancer, 2019.
  24. Graham DS, Russell TA, Eckardt MA, Motamedi K, Seeger LL, Singh AS, Bernthal NM, Kalbasi A, Dry SM, Nelson SD, Elashoff D, Levine BD, Eilber FC. Oncologic Accuracy of Image-guided Percutaneous Core-Needle Biopsy of Peripheral Nerve Sheath Tumors at a High-volume Sarcoma Center.. American journal of clinical oncology, 2019.
  25. Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade.. Nature reviews. Immunology, 2019.
  26. Rice SR, Saboury B, Houshmand S, Salavati A, Kalbasi A, Goodman CR, Werner TJ, Vujaskovic Z, Simone CB, Alavi A. Quantification of global lung inflammation using volumetric 18F-FDG PET/CT parameters in locally advanced non-small-cell lung cancer patients treated with concurrent chemoradiotherapy: a comparison of photon and proton radiation therapy.. Nuclear medicine communications, 2019.
  27. Shurell-Linehan E, DiPardo BJ, Elliott IA, Graham DS, Eckardt MA, Dry SM, Nelson SD, Singh AS, Kalbasi A, Federman N, Bernthal NM, Eilber FC. Pathologic Response to Neoadjuvant Therapy is Associated With Improved Long-term Survival in High-risk Primary Localized Malignant Peripheral Nerve Sheath Tumors.. American journal of clinical oncology, 2019.
  28. Paz H, Tsoi J, Kalbasi A, Grasso CS, McBride WH, Schaue D, Butterfield LH, Maurer DM, Ribas A, Graeber TG, Economou JS. Interleukin 32 expression in human melanoma.. Journal of translational medicine, 2019.
  29. Nowicki TS, Berent-Maoz B, Cheung-Lau G, Huang RR, Wang X, Tsoi J, Kaplan-Lefko P, Cabrera P, Tran J, Pang J, Macabali M, Garcilazo IP, Carretero IB, Kalbasi A, Cochran AJ, Grasso CS, Hu-Lieskovan S, Chmielowski B, Comin-Anduix B, Singh A, Ribas A. A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2018.
  30. Pennington JD, Eilber FC, Eilber FR, Singh AS, Reed JP, Chmielowski B, Eckardt JJ, Bukata SV, Bernthal NM, Federman N, Nelson SD, Dry SM, Wang PC, Luu M, Selch MT, Steinberg ML, Kalbasi A, Kamrava M. Long-term Outcomes With Ifosfamide-based Hypofractionated Preoperative Chemoradiotherapy for Extremity Soft Tissue Sarcomas.. American journal of clinical oncology, 2018.
  31. Ribas A, Medina T, Kummar S, Amin A, Kalbasi A, Drabick JJ, Barve M, Daniels GA, Wong DJ, Schmidt EV, Candia AF, Coffman RL, Leung ACF, Janssen RS. SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study.. Cancer discovery, 2018.
  32. Kalbasi A, Ribas A. Antigen Presentation Keeps Trending in Immunotherapy Resistance.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2018.
  33. Kalbasi A, Kirk M, Teo BK, Diffenderfer E, Ding X, McDonough J, Murphy E, Hill-Kayser C. Proton craniospinal irradiation during the third trimester of pregnancy.. Practical radiation oncology, 2017.
  34. Russell TA, Eckardt MA, Murakami T, Elliott IA, Kawaguchi K, Kiyuna T, Igarashi K, Li Y, Crompton JG, Graham DS, Dry SM, Bernthal N, Yanagawa J, Kalbasi A, Federman N, Chmielowski B, Singh AS, Hoffman RM, Eilber FC. Clinical Factors That Affect the Establishment of Soft Tissue Sarcoma Patient-Derived Orthotopic Xenografts: A University of California, Los Angeles, Sarcoma Program Prospective Clinical Trial.. JCO precision oncology, 2017.
  35. Kalbasi A, Rengan R. Clinical experiences of combining immunotherapy and radiation therapy in non-small cell lung cancer: lessons from melanoma.. Translational lung cancer research, 2017.
  36. Liu M, Kalbasi A, Beatty GL. Functio Laesa: Cancer Inflammation and Therapeutic Resistance.. Journal of oncology practice, 2017.
  37. Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, Grasso CS, Hugo W, Sandoval S, Torrejon DY, Palaskas N, Rodriguez GA, Parisi G, Azhdam A, Chmielowski B, Cherry G, Seja E, Berent-Maoz B, Shintaku IP, Le DT, Pardoll DM, Diaz LA, Tumeh PC, Graeber TG, Lo RS, Comin-Anduix B, Ribas A. Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.. Cancer discovery, 2016.
  38. Kalbasi A, Beatty GL, Berman AT. Expanding Tumor Lymphocytic Infiltration as a Prognostic Tool to Patients with NSCLC Who Are Treated with Radiotherapy?. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2016.
  39. Kalbasi A, Komar C, Tooker GM, Liu M, Lee JW, Gladney WL, Ben-Josef E, Beatty GL. Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016.
  40. Simone CB, Houshmand S, Kalbasi A, Salavati A, Alavi A. PET-Based Thoracic Radiation Oncology.. PET clinics, 2016.
  41. Fernandes RS, Mota LG, Kalbasi A, Moghbel M, Werner TJ, Alavi A, Rubello D, Cardoso VN, de Barros AL. 99mTc-phytate as a diagnostic probe for assessing inflammatory reaction in malignant tumors.. Nuclear medicine communications, 2015.
  42. Kalbasi A, Li J, Berman A, Swisher-McClure S, Smaldone M, Uzzo RG, Small DS, Mitra N, Bekelman JE. Dose-Escalated Irradiation and Overall Survival in Men With Nonmetastatic Prostate Cancer.. JAMA oncology, 2015.
  43. Kalbasi A, Swisher-McClure S, Mitra N, Sunderland R, Smaldone MC, Uzzo RG, Bekelman JE. Low rates of adjuvant radiation in patients with nonmetastatic prostate cancer with high-risk pathologic features.. Cancer, 2014.
  44. Kalbasi A, June CH, Haas N, Vapiwala N. Radiation and immunotherapy: a synergistic combination.. The Journal of clinical investigation, 2013.
  45. Xie C, Kim HJ, Haw JG, Kalbasi A, Gardner BK, Li G, Rao J, Chia D, Liong M, Punzalan RR, Marks LS, Pantuck AJ, de la Taille A, Wang G, Mukouyama H, Zeng G. A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases.. Journal of translational medicine, 2011.
  46. Kalbasi A, Fonsatti E, Natali PG, Altomonte M, Bertocci E, Cutaia O, Calabrò L, Chiou M, Tap W, Chmielowski B, Maio M, Ribas A. CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893.. Journal of immunotherapy (Hagerstown, Md. : 1997), 2010.
  47. Kalbasi A, Shrimali RK, Chinnasamy D, Rosenberg SA. Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein.. Journal of immunotherapy (Hagerstown, Md. : 1997), 2010.